UMIN ID: UMIN000002737
Registered date:11/11/2009
Cohort study evaluating (neo) adjuvant trastuzumab for HER2 positive breast cancer
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Breast cancer |
| Date of first enrollment | 2009/07/01 |
| Target sample size | 1500 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Disease-free survival; DFS |
|---|---|
| Secondary Outcome | Overall Survival; OS, Safety |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Female |
| Include criteria | |
| Exclude criteria | not applicable |
Related Information
| Primary Sponsor | Japan Breast Cancer Research Group (JBCRG) |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Japan Breast Cancer Research Group (JBCRG) |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Katsumasa Kuroi |
| Address | 9-4-3F, Nihonbashikoamicho, Chuo-ku, Tokyo 103-0016, Japan Japan 103-0016 |
| Telephone | 03-6264-8873 |
| office@jbcrg.jp | |
| Affiliation | Japan Breast Cancer Research Group (JBCRG) Head Office |
| scientific contact | |
| Name | Hiroyasu Yamashiro |
| Address | 54 Kawara-cho Shogoin, Japan |
| Telephone | 075-751-3660 |
| yamashiro.bcs@gmail.com | |
| Affiliation | Graduated school of medicine, Kyoto university Department of Surgery and Oncology |